Analysts expect Luminex Co. (NASDAQ:LMNX) to report $0.07 earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Luminex’s earnings. The highest EPS estimate is $0.11 and the lowest is $0.02. Luminex reported earnings per share of $0.25 in the same quarter last year, which would suggest a negative year-over-year growth rate of 72%. The business is scheduled to report its next earnings report on Monday, May 6th.
On average, analysts expect that Luminex will report full year earnings of $0.26 per share for the current fiscal year, with EPS estimates ranging from $0.05 to $0.41. For the next fiscal year, analysts expect that the company will report earnings of $0.50 per share, with EPS estimates ranging from $0.23 to $0.73. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Luminex.
Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, February 4th. The medical instruments supplier reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.08). The firm had revenue of $81.10 million during the quarter, compared to the consensus estimate of $80.76 million. Luminex had a net margin of 5.81% and a return on equity of 4.61%. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 earnings per share.
A number of brokerages have recently commented on LMNX. BidaskClub lowered Luminex from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Zacks Investment Research lowered Luminex from a “hold” rating to a “sell” rating in a report on Monday, April 8th. Finally, ValuEngine lowered Luminex from a “strong-buy” rating to a “buy” rating in a report on Monday, March 11th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $28.40.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NumerixS Investment Technologies Inc bought a new stake in Luminex during the fourth quarter worth about $39,000. Quantamental Technologies LLC bought a new stake in Luminex during the fourth quarter worth about $100,000. Amundi Pioneer Asset Management Inc. raised its holdings in Luminex by 32.4% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 4,500 shares of the medical instruments supplier’s stock worth $104,000 after acquiring an additional 1,100 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new stake in Luminex during the fourth quarter worth about $100,000. Finally, Meeder Asset Management Inc. raised its holdings in Luminex by 11.1% during the first quarter. Meeder Asset Management Inc. now owns 4,925 shares of the medical instruments supplier’s stock worth $113,000 after acquiring an additional 491 shares in the last quarter. Institutional investors and hedge funds own 85.99% of the company’s stock.
Shares of Luminex stock traded down $0.08 during trading on Monday, reaching $21.89. The stock had a trading volume of 167,253 shares, compared to its average volume of 319,218. The firm has a market cap of $988.43 million, a price-to-earnings ratio of 45.60, a price-to-earnings-growth ratio of 5.72 and a beta of 0.77. Luminex has a 52 week low of $19.20 and a 52 week high of $35.37.
The business also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Thursday, March 21st were issued a dividend of $0.06 per share. The ex-dividend date of this dividend was Wednesday, March 20th. This represents a $0.24 annualized dividend and a yield of 1.10%. Luminex’s payout ratio is presently 50.00%.
Luminex Company Profile
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.